Cargando…

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents

Trastuzumab is a standard molecular targeted therapy for human epidermal growth factor receptor 2(HER2) -positive breast cancer, which can significantly improve the survival of patients with this molecular subtype of breast cancer. However, the clinical problem of onset or secondary resistance to tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhen-hao, Zheng, Zhuo-qun, Jia, Shi−cheng, Liu, Shu-ni, Xiao, Xiao-fen, Chen, Guan-yuan, Liang, Wei-quan, Lu, Xiao-feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584623/
https://www.ncbi.nlm.nih.gov/pubmed/36276152
http://dx.doi.org/10.3389/fonc.2022.1006429